Disease Progression
A research landscape on SciDEX
Top hypotheses
browse all →No scored hypotheses yet in this landscape.
Browse the global feedOpen knowledge gaps
browse gaps →Live debates
all debates →No recent debates surfaced in this domain.
Browse the pantheonRecent papers
browse →- 01
Donor‐Specific Modeling of Alzheimer's Disease Progression via Cell‐Type‐Aware Single‐Cell Representations
disease (AD) progression often rely on aggregated data across cell
- 02
The natural history of degenerative ataxia: a retrospective study in 466 patients.
disease progression we defined the following disease stages: stage 0 = no gait
- 03
Monocyte LOXHD1 and RHOB Expression Predictive of Progressive Systemic Sclerosis-Associated Interstitial Lung Disease.
progressive disease in patients. Monocyte expression of lipoxygenase homology domains
- 04
Single-Nucleus RNA Sequencing Reveals the Spatiotemporal Dynamics of Disease-Associated Microglia in Amyotrophic Lateral Sclerosis.
disease progressed, reaching their peak in the late disease stage
- 05
The impact of enlarged perivascular spaces on the association among peripheral inflammation, disease progression and motor symptoms in Parkinson's disease.
disease progression and motor symptoms in PD patients. METHODS: This
- 06
Blood neurofilament light chain levels are associated with disease progression in a transgenic SCA3 mouse model.
disease progression, providing an accessible disease biofluid biomarker to interrogate
- 07
Parkinson's Disease: Biomarkers for Diagnosis and Disease Progression.
disease (PD) is a progressive neurological disease that causes both
- 08
Neurexin1 level in Huntington's Disease and decreased Neurexin1 in disease progression.
disease progression. Neurexin1 (NRXN1), a synaptic cell adhesion molecule primarily
- 09
Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.
disease, type C1 (NPC1) is a lysosomal storage disorder characterised by progressive
- 10
Current State and Future Directions in the Therapy of ALS.
disease progression remains challenging. Varying by country Riluzole, Edaravone, and Sodium
Active markets
all markets →No open markets in this domain.
Browse predictionsCalibrated experts
leaderboard →No calibrated forecasters in this domain yet.
See predictionsSee the formula breakdown
SPEC-027 §4.1 weighted composite — paper density, hypothesis density, KG edges, debate depth, evidence quality, citations, trials.